Search results
Results From The WOW.Com Content Network
Hyperprolactinemia, characterized by abnormally high levels of prolactin, may cause galactorrhea (production and spontaneous flow of breast milk), infertility, and menstrual disruptions in women. In men, it can lead to hypogonadism, infertility and erectile dysfunction. Prolactin is crucial for milk production during pregnancy and lactation.
Hyperprolactinemia occurs more commonly in women. The prevalence of hyperprolactinemia ranges from 0.4% in an unselected normal adult population (10,000 normal Japanese adults working at a single factory) to as high as 9 to 17% in women with reproductive disorders.
In women, prolactin is the hormone that regulates milk production. High prolactin levels can lead to a bunch of issues like infertility, intimate problems and bone loss, as well as breast pain and ...
Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications. [3] It is taken by mouth. Cabergoline is an ergot derivative and a potent dopamine D 2 receptor agonist. [4]
One cause of pituitary growth associated with the risk of Sheehan's syndrome is the hyperplasia of lactotrophs which produce prolactin, the hormone responsible for milk production. [5] Other hormone-secreting cells of the pituitary undergo rapid growth in pregnant women as well, which contribute to the gland's enlargement. [10]
The most common complex found in blood consists of prolactin and immunoglobulin G (IgG). [1] While the free prolactin hormone is active, prolactin in the macroprolactin complex does not have any biological activity in the body and is considered benign. [2] However, macroprolactin is detected by all Laboratory tests that measure prolactin in ...
Post-menopausal women under hormone replacement therapy have also reported symptoms of fibrocystic breast changes, indicating hormones may play a major role. [ citation needed ] This condition is an accumulative process, partly caused by the normal hormonal variation during a woman's monthly cycle.
Raloxifene increases bone mineral density in postmenopausal women but decreases it in premenopausal women. [14] In the MORE trial, the risk of vertebral fractures was decreased by 30%, and bone mineral density was increased in the spine (by 2.1% at 60 mg, 2.4% at 120 mg) and femoral neck (2.6% at 60 mg, 2.7% at 120 mg). [ 20 ]